Hyperlipidaemia News

  • 22 May 2020
    In this latest FOURIER analysis, add-on evolocumab treatment in patients with a recent myocardial infarction (MI) produced 3-fold greater absolute reduction in cardiovascular risk.  These findings confirm 2018 US guideline recommendations for adding a PCSK9 inhibitor in very high-risk patients with elevated LDL cholesterol (≥70 mg/dL or 1.8 mmol/L...
  • 30 April 2020
    A statement from the Lipid Association of India proposes aggressive LDL cholesterol lowering for individuals at high and very high risk of cardiovascular disease. Cardiovascular disease (CVD) is now the leading cause of mortality in India, responsible for one-quarter of all deaths (1). A number of factors contribute to this excess, including...
  • 30 April 2020
    According to a new analysis from the FOURIER trial, a reduced risk of venous thromboembolism (VTE) is an additional benefit from PCSK9 inhibition in very high-risk patients. Lipoprotein(a) may be a key mediator of this effect. There are mixed observational data for a link between LDL cholesterol and risk for VTE. A recent Mendelian randomisation...
  • 30 April 2020
    A new analysis from ODYSSEY OUTCOMES shows that alirocumab treatment reduces the substantial risk of peripheral artery disease (PAD) in acute coronary syndrome (ACS) patients on intensive statin therapy. Reduction lipoprotein(a), especially in individuals with high baseline levels, may mediate this benefit. In this prespecified analysis, the...
  • 30 April 2020
    Alirocumab was effective in lowering LDL cholesterol in children and adolescents with heterozygous familial hypercholesterolaemia (FH, inherited high cholesterol) treated with a statin. Heterozygous FH is characterised by elevated levels of LDL cholesterol which, if untreated, lead to premature atherosclerosis and cardiovascular events (1). Yet,...
  • 30 April 2020
    Results from the ORION-9 study in patients with heterozygous familial hypercholesterolaemia (FH, inherited high cholesterol) show that inclisiran lowers LDL cholesterol by nearly 50% and is well tolerated. The advent of monoclonal antibodies directed against PCSK9 has revolutionised the management of FH, with proven efficacy against a background...
  • 30 April 2020
    Prof. Anthony Wierzbicki, Guy's & St Thomas' Hospitals, London, UK discusses this analysis evaluating the impact of PCSK9 inhibition on hospitalisation following ACS. Most cardiovascular outcomes studies involving lipid-lowering treatment in patients with atherosclerotic cardiovascular disease (ASCVD) focus on the time to first occurrence of...
  • 30 April 2020
    Prof Raul Santos, from the Heart Institute (InCor) University of Sao Paulo Medical School Hospital and the Hospital Israelita Albert Einstein, São Paulo, Brazil discusses the latest findings from FOURIER. Stroke brings a high burden of individual and family suffering, in addition to elevated health costs. Together with elevated blood pressure and...
  • 31 March 2020
    News from the ACC.WCC 2020 Scientific Sessions Virtual meeting Integration of a polygenic risk score (PGS) with LDL cholesterol and systolic blood pressure (SBP), major cardiovascular risk factors,1 offers the potential to personalize cardiovascular disease prevention and target early intervention to those who need it most, according to this...
  • 31 March 2020
    News from the ACC.WCC 2020 Scientific Sessions Virtual meeting Treatment with the PCKS9 monoclonal antibody alirocumab reduced LDL cholesterol by 35.6% on top of maximally tolerated lipid lowering therapy, in patients with homozygous familial hypercholesterolaemia (HoFH), the rare and severe form of this inherited high cholesterol disorder....
  • 31 March 2020
    News from the ACC.WCC 2020 Scientific Sessions Virtual meeting Pooled analysis including more than 2700 patient years of exposure showed that twice-yearly inclisiran reduced LDL cholesterol by at least 50% and was well tolerated. Inclisiran is a novel small interfering RNA that specifically inhibits PCSK9 production in the liver.1 This approach...
  • 31 March 2020
    News from the ACC.WCC 2020 Scientific Sessions Virtual meeting Results of this latebreaker indicate therapeutic potential for evinacumab, a fully human monoclonal antibody inhibitor of angiopoietin-like 3 protein (ANGPTL3), in patients with homozygous familial hypercholesterolaemia, the most severe form of this inherited high cholesterol disorder...
  • 25 March 2020
    Preliminary data from the Gulf Familial Hypercholesterolaemia Registry (Gulf FH) show a high prevalence, with one in 232 people having definite or probable familial hypercholesterolaemia (FH, inherited high cholesterol). Heterozygous FH is largely underdiagnosed and undertreated.1 Information on prevalence is lacking in almost all countries, and...
  • 25 March 2020
    Understanding the genetic cause of familial hypercholesterolaemia (FH, inherited high cholesterol) is imperative to better stratify and manage cardiovascular risk in patients, according to this report from the UK BioBank. FH is the most common inherited metabolic condition, affecting about one in 200-250 people.1 Genetic variants in the LDLR, APOB...
  • 25 March 2020
    Familial hypercholesterolaemia (FH, inherited high cholesterol) is one of the most common inherited disorders, affecting approximately one in every 250 people or over 30 million people worldwide.  FH is usually caused by pathogenic variants in either of the LDLR, APOB or PCSK9 genes (encoding the LDL receptor, apolipoprotein B or PCSK9,...
  • 25 March 2020
    Alirocumab shows benefit in patients with type 2 diabetes mellitus (T2DM) and mixed dyslipidaemia, according to this analysis of the ODYSSEY DM-DYSLIPIDEMIA trial. Individuals with T2DM are at increased risk for atherosclerotic cardiovascular disease (ASCVD), in part due to the mixed dyslipidemia, characterized by elevated triglycerides (TGs) and...
  • 28 February 2020
    Trial BEIJERINCK: A Double Blind, Randomized, Placebo Controlled, Multicenter Study to Evaluate Safety, Tolerability, and Efficacy on LDL-C of Evolocumab (AMG 145) in Subjects With HIV and With Hyperlipidemia and/or Mixed Dyslipidemia. ClinicalTrials.gov Identifier: NCT02833844 Aim To investigate the efficacy and safety of evolocumab (420 mg...
  • 28 February 2020
    First trial of PCSK9 monoclonal antibody therapy in people living with HIV and at moderate/high cardiovascular risk, with elevated LDL cholesterol levels has closed enrolment, with 464 patients. Due to advances in antiretroviral treatment, HIV is now regarded as a chronic disease. Consequently, attention has refocused on the associated high...
  • 28 February 2020
    Trial DE LAVAL: A Randomized, Actively Controlled, Open-label, Multicenter Study of Efficacy and Safety of Evolocumab Compared With Low Density Lipoprotein Cholesterol (LDL-C) Apheresis, Followed by Single-Arm Evolocumab Administration in Subjects Receiving LDL-C Apheresis Prior to Study Enrollment. ClinicalTrials.gov Identifier: NCT02585895...
  • 28 February 2020
    Treatment with evolocumab may replace lipoprotein apheresis in patients with high LDL cholesterol levels, refractory to conventional treatment, according to the findings from the DE LAVAL study. Lipoprotein apheresis, which removes LDL cholesterol from the circulation, is indicated in patients with refractory heterozygous familial...

Pages